Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 19 | 2007 | 314 | 1.140 |
Why?
|
| Islets of Langerhans Transplantation | 21 | 2006 | 174 | 1.040 |
Why?
|
| Pancreas Transplantation | 7 | 2007 | 20 | 0.820 |
Why?
|
| Graft Survival | 13 | 2007 | 290 | 0.800 |
Why?
|
| Leukocyte Common Antigens | 10 | 2006 | 58 | 0.790 |
Why?
|
| Plasma Gases | 4 | 2022 | 5 | 0.770 |
Why?
|
| Graft Rejection | 9 | 2004 | 289 | 0.520 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2018 | 190 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 7 | 2006 | 836 | 0.390 |
Why?
|
| Bandages | 1 | 2012 | 15 | 0.390 |
Why?
|
| Warfare | 1 | 2012 | 33 | 0.390 |
Why?
|
| Hemostatics | 1 | 2012 | 26 | 0.380 |
Why?
|
| Islets of Langerhans | 12 | 2006 | 271 | 0.360 |
Why?
|
| Tissue Donors | 8 | 2007 | 143 | 0.360 |
Why?
|
| Military Personnel | 1 | 2012 | 97 | 0.360 |
Why?
|
| Hemorrhage | 1 | 2012 | 260 | 0.340 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 229 | 0.320 |
Why?
|
| Tissue and Organ Procurement | 4 | 2007 | 37 | 0.320 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.310 |
Why?
|
| Transplantation Tolerance | 3 | 2006 | 65 | 0.290 |
Why?
|
| CD40 Ligand | 4 | 2005 | 156 | 0.290 |
Why?
|
| Transplantation Immunology | 4 | 2005 | 27 | 0.260 |
Why?
|
| Transplantation, Homologous | 10 | 2006 | 244 | 0.240 |
Why?
|
| Bacterial Infections | 2 | 2004 | 140 | 0.220 |
Why?
|
| Immunosuppressive Agents | 6 | 2001 | 365 | 0.220 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 278 | 0.220 |
Why?
|
| Osteomyelitis | 1 | 2003 | 24 | 0.210 |
Why?
|
| Aspergillosis | 1 | 2003 | 40 | 0.210 |
Why?
|
| Spinal Diseases | 1 | 2003 | 45 | 0.210 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.210 |
Why?
|
| Insulin | 10 | 2005 | 673 | 0.210 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1118 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 31 | 0.190 |
Why?
|
| Sarcoma | 1 | 2022 | 36 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 9 | 2006 | 868 | 0.190 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 32 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 59 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 27 | 0.180 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 40 | 0.180 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 137 | 0.180 |
Why?
|
| Hemostasis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Chorion | 1 | 2018 | 5 | 0.160 |
Why?
|
| Amnion | 1 | 2018 | 9 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2004 | 37 | 0.150 |
Why?
|
| Achilles Tendon | 1 | 2018 | 7 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 145 | 0.150 |
Why?
|
| Tendon Injuries | 1 | 2018 | 17 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 38 | 0.150 |
Why?
|
| Histones | 1 | 2021 | 461 | 0.150 |
Why?
|
| Animals | 27 | 2020 | 19664 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 402 | 0.140 |
Why?
|
| Antibodies | 1 | 1998 | 179 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 10 | 2006 | 3236 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 37 | 0.140 |
Why?
|
| Body Constitution | 1 | 1997 | 16 | 0.140 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 31 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2005 | 172 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1469 | 0.130 |
Why?
|
| Humans | 31 | 2022 | 59457 | 0.130 |
Why?
|
| Osteoporosis | 3 | 2002 | 102 | 0.130 |
Why?
|
| Immunotherapy | 1 | 1998 | 228 | 0.120 |
Why?
|
| Kidney | 2 | 1997 | 414 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 1994 | 76 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 1994 | 99 | 0.110 |
Why?
|
| Incidence | 5 | 2004 | 1239 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 618 | 0.110 |
Why?
|
| Mice | 14 | 2006 | 10301 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 858 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 66 | 0.110 |
Why?
|
| Male | 19 | 2020 | 27784 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 1994 | 90 | 0.110 |
Why?
|
| Ischemia | 1 | 1995 | 199 | 0.110 |
Why?
|
| Time Factors | 8 | 2006 | 3621 | 0.110 |
Why?
|
| Heart Arrest | 1 | 1995 | 161 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1368 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2003 | 2901 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2002 | 1204 | 0.090 |
Why?
|
| Cyclosporins | 4 | 1987 | 17 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 224 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2020 | 378 | 0.090 |
Why?
|
| Cell Death | 2 | 2022 | 271 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 300 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 24 | 0.080 |
Why?
|
| Female | 13 | 2022 | 30766 | 0.080 |
Why?
|
| Apoptosis | 2 | 2022 | 1033 | 0.080 |
Why?
|
| Antigens | 2 | 2006 | 146 | 0.080 |
Why?
|
| Seasons | 2 | 2020 | 123 | 0.080 |
Why?
|
| Antilymphocyte Serum | 3 | 1998 | 20 | 0.070 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2003 | 10 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 2007 | 21 | 0.070 |
Why?
|
| Middle Aged | 10 | 2007 | 16338 | 0.070 |
Why?
|
| Acyclovir | 2 | 1997 | 19 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 154 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2007 | 53 | 0.060 |
Why?
|
| Death | 1 | 2006 | 25 | 0.060 |
Why?
|
| Spleen | 2 | 1986 | 480 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2020 | 365 | 0.060 |
Why?
|
| Reoperation | 1 | 2007 | 272 | 0.060 |
Why?
|
| Skin Transplantation | 3 | 2005 | 155 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 1997 | 6082 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 111 | 0.060 |
Why?
|
| Rats | 4 | 2018 | 1911 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2002 | 19 | 0.060 |
Why?
|
| Antigens, CD | 5 | 2006 | 343 | 0.060 |
Why?
|
| Immunoconjugates | 2 | 2003 | 85 | 0.060 |
Why?
|
| CTLA-4 Antigen | 4 | 2006 | 70 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 515 | 0.050 |
Why?
|
| Dogs | 6 | 1986 | 314 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2005 | 648 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 206 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 145 | 0.050 |
Why?
|
| Blood Glucose | 4 | 1997 | 461 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.050 |
Why?
|
| Chronic Disease | 2 | 1997 | 717 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 49 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 108 | 0.050 |
Why?
|
| Adult | 8 | 2006 | 15697 | 0.050 |
Why?
|
| Living Donors | 2 | 2004 | 72 | 0.050 |
Why?
|
| Leucovorin | 1 | 2021 | 9 | 0.050 |
Why?
|
| Bone Remodeling | 1 | 2001 | 25 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 124 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2021 | 56 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 2341 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 132 | 0.040 |
Why?
|
| Cell Division | 1 | 2022 | 443 | 0.040 |
Why?
|
| Bone Resorption | 1 | 2000 | 41 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 85 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 304 | 0.040 |
Why?
|
| Muromonab-CD3 | 2 | 1997 | 7 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 2005 | 155 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 192 | 0.040 |
Why?
|
| Infection Control | 1 | 2001 | 95 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 259 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 451 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 805 | 0.040 |
Why?
|
| Cadaver | 2 | 2004 | 110 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 196 | 0.040 |
Why?
|
| Rupture | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 428 | 0.040 |
Why?
|
| Monocytes | 1 | 2001 | 345 | 0.040 |
Why?
|
| Pancreatectomy | 4 | 1986 | 96 | 0.040 |
Why?
|
| Creatinine | 2 | 2002 | 128 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 550 | 0.040 |
Why?
|
| Ganciclovir | 1 | 1997 | 18 | 0.040 |
Why?
|
| Hospitalization | 2 | 1996 | 1293 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1997 | 38 | 0.030 |
Why?
|
| Osteocalcin | 3 | 2002 | 47 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 1997 | 8 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1997 | 11 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1997 | 62 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1997 | 76 | 0.030 |
Why?
|
| Cytokines | 1 | 2001 | 912 | 0.030 |
Why?
|
| Bone Density | 3 | 2002 | 129 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1996 | 47 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1997 | 178 | 0.030 |
Why?
|
| Exons | 1 | 1997 | 191 | 0.030 |
Why?
|
| Thymectomy | 2 | 2006 | 34 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1997 | 487 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 48 | 0.030 |
Why?
|
| Acute Disease | 2 | 1998 | 660 | 0.030 |
Why?
|
| Glucose Tolerance Test | 2 | 1986 | 96 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 108 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 369 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1997 | 313 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 29 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 903 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 32 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 296 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 574 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 751 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1994 | 114 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 17 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 113 | 0.030 |
Why?
|
| Abatacept | 2 | 2003 | 64 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1993 | 85 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2007 | 5287 | 0.020 |
Why?
|
| Risk Factors | 2 | 2004 | 4990 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2051 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1993 | 554 | 0.020 |
Why?
|
| Age Factors | 2 | 2007 | 1505 | 0.020 |
Why?
|
| Transplantation, Autologous | 3 | 1986 | 120 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1996 | 180 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 2007 | 207 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2003 | 516 | 0.020 |
Why?
|
| Amino Acids | 2 | 2001 | 140 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2005 | 1997 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 743 | 0.020 |
Why?
|
| Length of Stay | 1 | 1993 | 779 | 0.020 |
Why?
|
| Calcium | 2 | 2002 | 557 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Glucose | 2 | 1986 | 445 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 185 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 63 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 1306 | 0.020 |
Why?
|
| Fasting | 1 | 1986 | 48 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 38 | 0.020 |
Why?
|
| Methods | 1 | 2005 | 41 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1986 | 115 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 2005 | 37 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2005 | 33 | 0.020 |
Why?
|
| Adolescent | 3 | 2004 | 5851 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2007 | 162 | 0.010 |
Why?
|
| Raffinose | 1 | 2005 | 2 | 0.010 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 4 | 0.010 |
Why?
|
| Allopurinol | 1 | 2005 | 15 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1986 | 355 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 54 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 222 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 70 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 46 | 0.010 |
Why?
|
| New England | 1 | 2004 | 267 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2006 | 331 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 364 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 831 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2004 | 244 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 394 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 2003 | 30 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 65 | 0.010 |
Why?
|
| Ficoll | 1 | 2002 | 4 | 0.010 |
Why?
|
| Filtration | 1 | 2002 | 20 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 164 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1206 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 149 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 1302 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 46 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 979 | 0.010 |
Why?
|
| Everolimus | 1 | 2001 | 21 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2001 | 23 | 0.010 |
Why?
|
| Infection Control Practitioners | 1 | 2001 | 2 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 2001 | 3 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 1984 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 621 | 0.010 |
Why?
|
| Physician Executives | 1 | 2001 | 28 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 13427 | 0.010 |
Why?
|
| Italy | 1 | 2001 | 63 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 47 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2001 | 43 | 0.010 |
Why?
|
| Sirolimus | 1 | 2001 | 88 | 0.010 |
Why?
|
| Nursing Staff | 1 | 2001 | 39 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 551 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 85 | 0.010 |
Why?
|
| Calcineurin | 1 | 2001 | 43 | 0.010 |
Why?
|
| Hypertension | 1 | 2004 | 570 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1553 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2005 | 733 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 1794 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1997 | 19 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 323 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1188 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 184 | 0.010 |
Why?
|
| Rats, Inbred Lew | 2 | 1987 | 106 | 0.010 |
Why?
|
| Prognosis | 1 | 2001 | 1597 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 715 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1996 | 66 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 163 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 986 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 737 | 0.010 |
Why?
|
| Child | 1 | 2004 | 4201 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 3072 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 2383 | 0.010 |
Why?
|
| United States | 1 | 2007 | 7432 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1987 | 6 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1987 | 25 | 0.000 |
Why?
|
| Methacholine Compounds | 1 | 1986 | 12 | 0.000 |
Why?
|
| Methacholine Chloride | 1 | 1986 | 26 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1986 | 20 | 0.000 |
Why?
|
| Portal Vein | 1 | 1986 | 38 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1986 | 132 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 248 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 354 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1985 | 5 | 0.000 |
Why?
|
| Swine | 1 | 1985 | 355 | 0.000 |
Why?
|